Posted by Michael Wonder on 12 Aug 2016
CADTH issues initial pERC outcome for Lynparza (olaparib)
5 August 2016 - CADTH has published pERC's initial recommendation on the use of olaparib for use as monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy.
The pERC has not recommended the use of olaparib due to uncertainty on the net clinical benefit when compared with placebo.
